Orphan Drugs 2025 _ Event Postponement
This is to inform that due to some circumstances beyond the organizer control, “2nd International Conference on Orphan Drugs and Rare Diseases” (ORPHAN DRUGS 2025) scheduled during March 13-15, 2025 in Rome, Italy has been postponed. The updated dates and venue will be displayed shortly.
Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.
For further details, please contact us at orphan-drugs@magnusconference.com or call + 1 (702) 988 2320.
2nd International Conference on Orphan Drugs and Rare Diseases
March 13-15, 2025
Revolutionary Changes
Regrettably, "rare disease" has historically been low on the public health agenda, a fact that the 350 million individuals worldwide who suffer from these diseases are well aware of. This is unsurprising since, while each of these rare diseases has too little a health burden to make a simple health-economic justification, rare diseases are thought to be just as common as other disorders. Rare disease detection and management is an example of an area that has profited from technological advancements. The integration of new medicines for rare diseases into existing care systems, on the other hand, calls into question a translational medicine premise that there is a linear pathway from bench to bedside. In awareness of the impact of patterns of clinical interventions and associated health services on patients' and their families' quality of life, a range of patient-oriented outcomes may be most relevant to examine for incremental therapies.
- Recent Trends
- Novel Innovations
Sergey Suchkov
The Russian University of Medicine & Russian Academy of Natural Sciences, Russian Federation
Vladlen Slepak
University of Miami, United States
Harsha Rajasimha
Jeeva Clinical Trials, Inc, United States
Vladlen Slepak
University of Miami, United States
Harsha Rajasimha
Jeeva Clinical Trials, Inc, United States
Sergey Suchkov
The Russian University of Medicine & Russian Academy of Natural Sciences, Russian Federation
Melissa Keenan
La Jolla Labs, United StatesSubmit your abstract Today
Title : Emerging solutions for inclusive orphan drug clinical trials management
Harsha Rajasimha, Jeeva Clinical Trials, Inc, United States
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets. Discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami, United States
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model to secure the human healthcare and biosafety among childhood
Sergey Suchkov, The Russian University of Medicine & Russian Academy of Natural Sciences, Russian Federation
Title : Orphan and rare disease emerging as a global public health priority through the view of personalized and precision medicine: How to use the latter to revolutionize pediatric services
Sergey Suchkov, The Russian University of Medicine & Russian Academy of Natural Sciences, Russian Federation
Title : Personalized and Precision Medicine (PPM) though the view of reproductive healthcare, pediatric services and natural family planning: an option for clinicians and caregivers realize the potential of genomics-informed care to secure the individualized human biosafety
Sergey Suchkov, The Russian University of Medicine & Russian Academy of Natural Sciences, Russian Federation
Title : Democratizing ASO drug discovery at La Jolla Labs
Melissa Keenan, La Jolla Labs, United States